QUALITATIVE EXPLORATION OF THE REAL-WORLD EXPERIENCES OF MEN RECEIVING OR REFUSING CHEMOTHERAPY (DOCETAXEL) FOR THE TREATMENT OF METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)

被引：0
|
作者：
Ito, T. [1 ]
Grant, L. [2 ]
Mills, A. [3 ]
Heselwood, A. [3 ]
Gater, A. [2 ]
机构：
[1] Janssen Cilag UK, High Wycombe, Bucks, England
[2] Adelphi Values Ltd, Bollington, Cheshire, England
[3] Adelphi Res UK, Bollington, Cheshire, England
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.295
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN212
引用
收藏
页码：A450 / A450
页数：1
相关论文
共 50 条
  • [31] DISEASE BURDEN OF METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) IN CHINA
    Yu, M.
    Duan, X.
    Wang, J.
    Zhang, X. J.
    Yu, F.
    VALUE IN HEALTH, 2021, 24 : S39 - S40
  • [32] Real-world utilisation of upfront chemohormonal therapy in metastatic hormone-sensitive prostate cancer
    Kelly, R.
    Wong, S. S. L.
    Shapiro, J.
    Weickhardt, A. J.
    Parente, P.
    Azad, A.
    Uccellini, A.
    Torres, J.
    Parnis, F.
    Kwan, E.
    Brown, S.
    Steer, C.
    Warren, M.
    Gibbs, P.
    Anton, A.
    Tran, B.
    ANNALS OF ONCOLOGY, 2022, 33 : S1498 - S1499
  • [33] Audit of febrile neutropenic (FN) episodes in men receiving docetaxel for hormone-sensitive metastatic prostate cancer (HSMPC)
    Raby, S.
    Mahil, J.
    Hughes, C.
    Lyons, J.
    Patel, K.
    Elliott, T.
    Conroy
    CLINICAL ONCOLOGY, 2016, 28 : S8 - S8
  • [34] An adjusted indirect treatment comparison (ITC) of enzalutamide (ENZ) versus docetaxel (DOC) for metastatic hormone-sensitive prostate cancer (mHSPC)
    Ohlmann, Carsten
    Armstrong, Andrew
    Gratzke, Christian
    Sugg, Jennifer
    Ganguli, Arijit
    Dornstauder, Eugen
    Gross-Langenhoff, Marco
    Brauner, Reinhard
    Stenzl, Arnulf
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 109 - 109
  • [35] Comparison of outcomes with docetaxel or ARPI combination therapy for metastatic hormone-sensitive prostate cancer (mHSPC) by volume of disease
    Schoen, Martin W.
    Etzioni, Ruth Douglas
    Luo, Suhong
    Candelieri, Danielle
    Fedele, Nicholas
    Baxi, Priya
    Pickett, Carley
    Riekhof, Forest
    Ingram, Kara
    Karunanandaa, Krishny
    Govindan, Srinivas
    Cheranda, Nina
    Knoche, Eric Marshall
    Montgomery, Robert Bruce
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [36] Early Docetaxel and Androgen Deprivation in the Treatment of Metastatic, Hormone-sensitive Prostate Cancer
    Tassinari, Davide
    Tamburini, Emiliano
    Gianni, Lorenzo
    Drudi, Fabrizio
    Fantini, Manuela
    Santelmo, Carlotta
    Stocchi, Lucia
    Montanari, Francesco
    Sartori, Sergio
    REVIEWS ON RECENT CLINICAL TRIALS, 2016, 11 (04) : 317 - 323
  • [37] IDENTIFYING AND CHARACTERIZING METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) POPULATION IN FINLAND
    Ruotsalainen, J.
    Korhonen, M. J.
    Purmonen, T.
    Joutseno, J.
    Saavuori, N.
    VALUE IN HEALTH, 2023, 26 (12) : S535 - S535
  • [38] Docetaxel Improves Survival in Metastatic Hormone-Sensitive Prostate Cancer
    Schuyler, Devon
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (09) : 549 - 549
  • [39] Management of Metastatic Hormone-Sensitive Prostate Cancer: Is Docetaxel Needed?
    Kartolo, Adi
    Tannock, Ian F.
    Badillo, Francisco E. Vera
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (31) : 3573 - +
  • [40] Real-world treatment patterns and survival in men with metastatic castration-resistant prostate cancer (mCRPC) who previously progressed from metastatic hormone-sensitive prostate cancer (mHSPC) between 2020 to 2023 in the United States.
    Raval, Amit D.
    Chen, Guifang
    Korn, Matthew J.
    Bernthaler, Andreas
    Constantinovici, Niculae
    Freedland, Stephen J.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
12345